Related Experiment Videos
Genetically predicted stigmasterol and brain tumor risk: A Mendelian randomization study
Binbin Zhang1, Bolin Gao, Peng Yun
1Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P.R. China.
Medicine
|May 19, 2026
Summary
This study found no direct causal link between genetically predicted stigmasterol levels and brain tumor risk. However, stigmasterol is linked to lipid metabolism, suggesting pathways relevant to brain tumor susceptibility.
Area of Science:
- Biochemistry
- Genetics
- Oncology
Background:
- Stigmasterol, a plant sterol, influences lipid metabolism and has been linked to cancer.
- The direct impact of stigmasterol on brain tumor development is not well understood.
Purpose of the Study:
- To investigate the causal relationship between genetically predicted stigmasterol levels and brain tumor risk.
- To explore the association between stigmasterol, lipid metabolism, and brain tumor development using Mendelian randomization.
Main Methods:
- Two-sample Mendelian randomization (MR) analysis utilizing large-scale genome-wide association study data.
- Examined genetically predicted stigmasterol as exposure, lipid traits as secondary exposures, and brain tumor risk as the outcome.
- Conducted sensitivity analyses and multivariable MR to assess robustness and independent effects.
Main Results:
- Genetically predicted stigmasterol showed no significant association with overall brain tumor risk or glioblastoma.
- Stigmasterol was associated with increased total cholesterol and fatty acid levels.
- Total cholesterol had suggestive, method-dependent links to brain tumor risk; fatty acids did not.
Conclusions:
- The study does not support a direct causal effect of stigmasterol on brain tumor risk.
- Lipid metabolic pathways, influenced by stigmasterol, may be relevant to brain tumor susceptibility.
- Further research into lipid metabolism's role in brain tumors is warranted.
Related Concept Videos
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...